Advertisement

Treatment of Recurrent and Metastatic Esophageal Cancer

  • Michele Pavarana
  • Teodoro Sava
Part of the Updates in Surgery book series (UPDATESSURG)

Abstract

There are few studies of the treatment of relapse in patients with esophageal squamous cell cancer (ESCC). Moreover, those trials were not randomized and without convincing data. Cumulative overall 1-year and 2-year survival rates after recurrence were around 30% and 12%, respectively, with a median survival of 6 months [1]. For this reason, the goal of the treatment is usually adequate palliation instead of cure, taking into account many factors: patient characteristics (performance status, age, co-morbidity), mode of relapse (local vs. locoregional vs. systemic), site of the primary cancer (non-local recurrences are more frequent in cervical or upper thoracic cancers) [2]; site of relapse (liver recurrence is the worst prognostic site, with a median overall survival < 6 months) [3]; kinetics of relapse (indolent or aggressive, symptomatic or asymptomatic disease); and previous treatments and their toxicities.

Keywords

Esophageal Cancer Esophageal Carcinoma Palliative Chemotherapy Good Supportive Care Esophageal Squamous Cell Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hsu PK, Wang BY, Huang CS et al (2011) Prognostic factors for post-recurrence survival in esophageal suamous cell carcinoma patients with recurrence after resection. J Gastrointest Surg DOI 10.1007/s11605-011-1458-1Google Scholar
  2. 2.
    Ishihara R, Yamamoto S, Iishi H et al (2010) Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 76:123–129PubMedCrossRefGoogle Scholar
  3. 3.
    Takashima A, Shirao K, Hirashima Y et al (2008) Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. Dis Esophagus 21:607–611PubMedCrossRefGoogle Scholar
  4. 4.
    Nemoto K, Ariga H, Kakuto Y et al (2001) Radiation therapy for loco-regionally recurrent esophageal cancer after surgery. Radiother Oncol 61:65–168CrossRefGoogle Scholar
  5. 5.
    Yamashita H, Nakagawa K, Tago M et al (2005) Salvage radiotherapy for postoperative loco-regional recurrence of esophageal cancer. Dis Esophagus 18:215–220PubMedCrossRefGoogle Scholar
  6. 6.
    Maruyama K, Motoyama S, Anbai A et al (2010) Therapeutic strategy for the treatment of postoperative recurrence od esophageal squamous cell carcinoma: clinical efficacy of radiotherapy. Dis Esophagus 13:1442–1450Google Scholar
  7. 7.
    Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 281:1623–1627PubMedCrossRefGoogle Scholar
  8. 8.
    Ishikura S, Nihei H, Ohtsu A et al (2003) Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2:2697–2702CrossRefGoogle Scholar
  9. 9.
    Tahara M, Othsu A, Hironaka S et al (2005) Clinical impact of criteria for complete response of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 35:316–323PubMedCrossRefGoogle Scholar
  10. 10.
    Meunier B, Raoul J, Le Prise E et al (1998) Salvage esophagectomy after unsuccessful curative chemoradiotherapy for squamous cell cancer of the esophagus. Dig Surg 15:224–226PubMedCrossRefGoogle Scholar
  11. 11.
    Swisher SG, Wynn P, Putnam JB et al (2002) Salvage esophagectomy for recurrent tumours after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 123:175–183PubMedCrossRefGoogle Scholar
  12. 12.
    Tomimaru Y, Yano M, Takachi K et al (2006) Factors affecting the prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiotherapy. J Surg Oncol 93:422–428PubMedCrossRefGoogle Scholar
  13. 13.
    Natsugoe S, Okumura H, Matsumoto M et al (2006) The role of salvage surgery for recurrence of esophageal squamous cell cancer. Eur J Surg Oncol 32:544–547PubMedCrossRefGoogle Scholar
  14. 14.
    Ariga H, Nemoto K, Miyazaki S et al (2009) Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in respectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 75:348–356PubMedCrossRefGoogle Scholar
  15. 15.
    Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ (2007) Salvage oesophagectomy after local failure of definitive chemoradiotherapy. Br J Surg 94:1059–1066PubMedCrossRefGoogle Scholar
  16. 16.
    Nishimura M, Daiko H, Yoshida J et al (2007) Gen Thorac Cardiovasc Surg 55:461–464Google Scholar
  17. 17.
    Daly JM, Karnell LH and Menck HR (1996) National cancer data base report on esophageal carcinoma. Cancer 78:1820–1828PubMedCrossRefGoogle Scholar
  18. 18.
    Parkin D, Pisani P and Ferley J (1999) Global cancer statistics. Cancer J Clin 49:33–64CrossRefGoogle Scholar
  19. 19.
    Cochrane Database Syst Rev. 2010. May 12: 5:CD004063Google Scholar
  20. 20.
    Ravry M, Moertel CG, Schutt AJ et al (1973) Treatment of advanced squamous cell carcinoma of the gastrointestinal tract with bleomycin. Cancer Chemother Rep 57:493–495PubMedGoogle Scholar
  21. 21.
    Kolari K, Marici Z, Dujmovi I et al (1976) Therapy of advanced esophageal cancer with bleomycin, irradiation and combination of bleomycin with irradiation. Tumori 62:255–262Google Scholar
  22. 22.
    Engstrom PF, Lavin PT, Klaassen DJ (1983) Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat Rep 67:713–725PubMedGoogle Scholar
  23. 23.
    Ezdinli EZ, Gelber R, Desai DV et al (1980) Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 46:2149–53PubMedCrossRefGoogle Scholar
  24. 24.
    Bezwoda WR, Derman DP, Weaving A et al (1984) Treatment of esophageal cancer with vindesine: an open trial. Cancer Treat Rep 68:783–785PubMedGoogle Scholar
  25. 25.
    Kelsen DP, Bains M, Cvitkovic E et al (1979) Vindesine in the treatment of esophageal carcinoma: a phase II study. Cancer Treat Rep 63:2019–2021PubMedGoogle Scholar
  26. 26.
    Ravry MJ, Moore MR, Omura GA et al (1985) Phase II evaluation of cisplatin in squamous carcinoma of the esophagus: a Southeastern Cancer Study Group trial. Cancer Treat Rep 69:1457–1458PubMedGoogle Scholar
  27. 27.
    Panettiere FJ, Leichman LP, Tilchen EJ et al (1984) Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study. Cancer Treat Rep 68:1023–1024PubMedGoogle Scholar
  28. 28.
    Conroy T, Etienne PL, Adenis A et al (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol 14:164–170PubMedGoogle Scholar
  29. 29.
    Sternberg C, Kelsen D, Dukeman M et al (1985) Carboplatin: a new platinum analog in the treatment of epidermoid carcinoma of the esophagus. Cancer Treat Rep 69:1305–1307PubMedGoogle Scholar
  30. 30.
    Queisser W, Preusser P, Mross KB et al (1990) Phase II evaluation of carboplatin in advanced esophageal carcinoma. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer Society. Onkologie 13:190–193PubMedCrossRefGoogle Scholar
  31. 31.
    Coonley CJ, Bains M, Heelan R et al (1983) Phase II study of etoposide in the treatment of esophageal carcinoma. Cancer Treat Rep 67:397–398PubMedGoogle Scholar
  32. 32.
    Muro K, Hamaguchi T, Ohtsu A et al (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15:955–959PubMedCrossRefGoogle Scholar
  33. 33.
    Kelsen D, Ajani J, Ilson D et al (1994) A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: preliminary report. Semin Oncol 21:44–48PubMedGoogle Scholar
  34. 34.
    Einzig AI, Neuberg D, Remick SC et al (1996) Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.Med Oncol 13:87–93PubMedCrossRefGoogle Scholar
  35. 35.
    Bidoli P, Stani SC, De Candis D et al (2001) Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus. Tumori 87:299–302PubMedGoogle Scholar
  36. 36.
    Vogl SE, Greenwald E, Kaplan BH (1981) Effective chemotherapy for esophageal cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II. Cancer 48:2555–2558PubMedCrossRefGoogle Scholar
  37. 37.
    Gisselbrecht C, Calvo F, Mignot et al (1983) Fluorouracil (F), Adriamycin (A), and cisplatin (P) (FAP): combination chemotherapy of advanced esophageal carcinoma. Cancer 52:974–977PubMedCrossRefGoogle Scholar
  38. 38.
    Dinwoodie WR, Bartolucci AA, Lyman GH et al (1986) Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 70:267–270PubMedGoogle Scholar
  39. 39.
    De Besi P, Salvagno L, Endrizzi L et al (1984) Cisplatin, bleomycin and methotrexate in the treatment of advanced oesophageal cancer. Eur J Cancer Clin Oncol 20:743–747PubMedCrossRefGoogle Scholar
  40. 40.
    Kelsen D, Hilaris B, Coonley C et al (1983) Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma. Am J Med 75:645–652PubMedCrossRefGoogle Scholar
  41. 41.
    De Besi P, Sileni VC, Salvagno L et al (1986) Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. Cancer Treat Rep 70:909–910PubMedGoogle Scholar
  42. 42.
    Lovett D, Kelsen D, Eisenberger M et al (1991) A phase II trial of carboplatin and vinblastine in the treatment of advanced squamous cell carcinoma of the esophagus. Cancer 67:354–356PubMedCrossRefGoogle Scholar
  43. 43.
    Iizuka T, Kakegawa T, Ide H et al (1992) Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22:172–176PubMedGoogle Scholar
  44. 44.
    Advani SH, Saikia TK, Swaroop S et al (1985) Anterior chemotherapy in esophageal cancer. Cancer 56:1502–1506PubMedCrossRefGoogle Scholar
  45. 45.
    Stahl M, Wilke H, Meyer HJ et al (1994) 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. Eur J Cancer 30A:325–328PubMedCrossRefGoogle Scholar
  46. 46.
    Kelsen D, Lovett D, Wong J et al (1992) Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J Clin Oncol 10:269–274PubMedGoogle Scholar
  47. 47.
    Wadler S, Fell S, Haynes H et al (1993) Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. Cancer 71:1726–1730PubMedCrossRefGoogle Scholar
  48. 48.
    Braybrooke JP, O’Byrne KJ, Saunders MP et al (1997) A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Ann Oncol 8:294–296PubMedCrossRefGoogle Scholar
  49. 49.
    Kelsen D, Ginsberg R, Bains M et al (1997) A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report. Semin Oncol 24:S19–77–S19–81PubMedGoogle Scholar
  50. 50.
    Van der Gaast A, Kok TC, Kerkhofs L et al (1999) Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. Br J Cancer 80:1052–1057PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Cho SH, Chung IJ, Song SY et al (2005) Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer. J Korean Med Sci Aug;20(4):618–23CrossRefGoogle Scholar
  52. 52.
    Ilson DH, Forastiere A, Arquette M et al (2000) A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 6:316–623PubMedGoogle Scholar
  53. 53.
    Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267PubMedCrossRefGoogle Scholar
  54. 54.
    Petrasch S, Welt A, Reinacher A et al (1998) Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 78:511–514PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Ilson DH, Ajani J, Bhalla K et al (1998) Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826–1834PubMedGoogle Scholar
  56. 56.
    Levard H, Pouliquen X, Hay JM et al (1998) 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg 164:849–857PubMedCrossRefGoogle Scholar
  57. 57.
    Philip PA, Zalupski MM, Gadgeel S et al (1997) A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Semin Oncol 24:S19–86–S19–88PubMedGoogle Scholar
  58. 58.
    Sekiguchi H, Akiyama S, Fujiwara M et al (1999) Phase II trial of 5-fluorouracil and lowdose cisplatin in patients with squamous cell carcinoma of the esophagus. Surg Today 29:97–101PubMedCrossRefGoogle Scholar
  59. 59.
    Ilson DH, Saltz L, Enzinger P et al (1999) Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270–3275PubMedGoogle Scholar
  60. 60.
    Ajani JA, Baker J, Pisters PW et al (2002) CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 94:641–646PubMedCrossRefGoogle Scholar
  61. 61.
    Lokich JJ, Sonneborn H, Anderson NR et al (1999) Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer 85:2347–2351PubMedCrossRefGoogle Scholar
  62. 62.
    Mackay HJ, McInnes A, Paul J et al (2001) A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. Ann Oncol 12:1407–1410PubMedCrossRefGoogle Scholar
  63. 63.
    Hayashi K, Ando N, Watanabe H et al (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 31:419–423PubMedCrossRefGoogle Scholar
  64. 64.
    Caroli-Bosc FX, Van Laethem JL, Michel P et al (2001) A weekly 24-h infusion of highdose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. Eur J Cancer 37:1828–1832PubMedCrossRefGoogle Scholar
  65. 65.
    Goncalves A, Camerlo J, Bun H et al (2001) Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics. Anticancer Res 21:1431–1437PubMedGoogle Scholar
  66. 66.
    Polee MB, Kok TC, Siersema PD et al (2001) Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anticancer Drugs 12:513–517PubMedCrossRefGoogle Scholar
  67. 67.
    Tebbutt NC, Norman A, Cunningham D et al (2002) A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 13:1568–1575PubMedCrossRefGoogle Scholar
  68. 68.
    Bazarbashi S, Rahal M, Raja MA et al (2002) A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma. Chemotherapy 48:211–216PubMedCrossRefGoogle Scholar
  69. 69.
    Conroy T, Etienne PL, Adenis A et al (2002) Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.Ann Oncol 13:721–729PubMedCrossRefGoogle Scholar
  70. 70.
    Ross P, Nicolson M, Cunningham D et al (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996–2004PubMedCrossRefGoogle Scholar
  71. 71.
    Govindan R, Read W, Faust J et al (2003) Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. Oncology (Williston Park) 17:27–31Google Scholar
  72. 72.
    Lordick F, von Schilling C, Bernhard H et al (2003) Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 18;630–633CrossRefGoogle Scholar
  73. 73.
    Airoldi M, Cattel L, Marchionatti S et al (2003) Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Am J Clin Oncol 26:378–381PubMedGoogle Scholar
  74. 74.
    Urba SG, Chansky K, VanVeldhuizen PJ et al (2004) Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest New Drugs 22:91–97PubMedCrossRefGoogle Scholar
  75. 75.
    El-Rayes BF, Shields A, Zalupski M et al (2004) A phase II study of carboplatin and paclitaxelBF, Shields A, Zalupski M et al (2004) A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol 15:960–965PubMedCrossRefGoogle Scholar
  76. 76.
    Kroep JR, Pinedo HM, Giaccone G et al (2004) Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann Oncol 15:230–235PubMedCrossRefGoogle Scholar
  77. 77.
    Ilson DH (2004) Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 18:22–25Google Scholar
  78. 78.
    Morgan-Meadows S, Mulkerin D, Berlin JD et al (2005) A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology 69:130–134PubMedCrossRefGoogle Scholar
  79. 79.
    Lorenzen S, Duyster J, Lersch C et al (2005) Capecitabine plus docetaxel every 3 weeks in first-and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 92:2129–2133PubMedCentralPubMedCrossRefGoogle Scholar
  80. 80.
    Mauer AM, Kraut EH, Krauss SA et al (2005) Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 16:1320–1325PubMedCrossRefGoogle Scholar
  81. 81.
    Meluch AA, Hainsworth JD, Gray JR et al (1999) Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localised esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Networkphase II trial. Cancer J Sci Am 5:84–91PubMedGoogle Scholar
  82. 82.
    Heath EI, Burtness BA, Heitmiller RF et al (2000) Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18:868–876PubMedGoogle Scholar
  83. 83.
    Mauer AM, Haraf DC, Ferguson MK et al (2000) Docetaxel-based combined modality Therapy for locally advanced carcinoma of the esophagus and gastric cardia. Proc Am Soc Clin Oncol 19:954aGoogle Scholar
  84. 84.
    Liu An, Huang J, Cai RG et al (2008) Response af advanced esophageal cancer to chemotherapy and prognostic factors: a report of 138 cases. Ai Zheng, 27:400–406PubMedGoogle Scholar
  85. 85.
    Grunberger B, Raderer M, Schmidinger M, Hejna M (2007) Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res 27:2705–2714PubMedGoogle Scholar
  86. 86.
    Takashima A, Shirao K, Hirashima Y et al (2008) Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. Dis Esophagus 21:607–611PubMedCrossRefGoogle Scholar
  87. 87.
    Hsu PK, Wang BY, Huang CS (2011) Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection. J Gastrointest Surg, DOI 10.1007/s11605-011-1458-1Google Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  • Michele Pavarana
    • 1
  • Teodoro Sava
  1. 1.Oncology UnitBorgo Trento HospitalVeronaItaly

Personalised recommendations